Sequent Scientific Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
May 23, 2023 at 10:47 am EDT
Share
Sequent Scientific Limited reported earnings results for the fourth quarter and full year ended March 31, 2023. For the fourth quarter, the company reported sales was INR 3,666.68 million compared to INR 3,837.09 million a year ago. Revenue was INR 3,684.05 million compared to INR 3,874.79 million a year ago. Net loss was INR 935.75 million compared to net income of INR 88.26 million a year ago. Basic loss per share from continuing operations was INR 3.77 compared to basic earnings per share from continuing operations of INR 0.35 a year ago. Diluted loss per share from continuing operations was INR 3.77 compared to diluted earnings per share from continuing operations of INR 0.34 a year ago.
For the full year, sales was INR 14,209.09 million compared to INR 14,128.16 million a year ago. Revenue was INR 14,272.99 million compared to INR 14,236.61 million a year ago. Net loss was INR 1,211.6 million compared to net income of INR 409.55 million a year ago. Basic loss per share from continuing operations was INR 4.88 compared to basic earnings per share from continuing operations of INR 1.65 a year ago. Diluted loss per share from continuing operations was INR 4.88 compared to diluted earnings per share from continuing operations of INR 1.63 a year ago.
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.